Get the Stockscreener App
9.07
5.91%
-0.57
Clearpoint Neuro Inc stock is traded at $9.07, with a volume of 965.00K.
It is down -5.91% in the last 24 hours and down -32.31% over the past month.
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
See More
Previous Close:
$9.64
Open:
$9.58
24h Volume:
965.00K
Relative Volume:
1.33
Market Cap:
$276.67M
Revenue:
$40.61M
Net Income/Loss:
$-29.07M
P/E Ratio:
-8.9971
EPS:
-1.0081
Net Cash Flow:
$-26.70M
1W Performance:
-13.45%
1M Performance:
-32.31%
6M Performance:
-13.62%
1Y Performance:
-64.12%
1-Day Range:
$9.00
$9.595
1-Week Range:
$9.00
$10.51
52-Week Range:
$8.27
$28.10
Clearpoint Neuro Inc Stock (CLPT) Company Profile
Name
Clearpoint Neuro Inc
Sector
Industry
Phone
(949) 900-6833
Address
120 S. SIERRA AVENUE, SOLANA BEACH, CA
Compare CLPT vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLPT
Clearpoint Neuro Inc
|
9.07 | 276.67M | 40.61M | -29.07M | -26.70M | -1.0081 |
ABT
Abbott Laboratories
|
104.89 | 181.50B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.75 | 121.20B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
294.66 | 113.02B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.39 | 64.33B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.60 | 49.92B | 6.30B | 1.07B | 1.09B | 1.8406 |
Clearpoint Neuro Inc Stock (CLPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-26 | Resumed | Stifel | Buy |
| Jul-25-24 | Resumed | B. Riley Securities | Buy |
| Oct-24-23 | Initiated | Stifel | Buy |
| Feb-16-23 | Resumed | B. Riley Securities | Buy |
| Apr-05-22 | Resumed | B. Riley Securities | Buy |
| Mar-18-21 | Initiated | Lake Street | Buy |
| Jul-17-20 | Initiated | B. Riley FBR | Buy |
View All
Clearpoint Neuro Inc Stock (CLPT) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc.CLPT - GlobeNewswire Inc.
AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue Estimates - Zacks Investment Research
ClearPoint Neuro Director R. John Fletcher Receives 993 Shares as Director Compensation - Kalkine Media
319 shares go to director Timothy T. Richards as fee payment from ClearPoint Neuro (CLPT). - Stock Titan
ClearPoint Neuro (NasdaqCM:CLPT) Stock Forecast & Analyst Predictions - simplywall.st
Top Conexeu Sciences (CNXU) Competitors 2026 - marketbeat.com
Conexeu Sciences (CNXU) Short Interest & Short Float | Updated Sep 2026 - marketbeat.com
Hemostemix files for price protection in $1M pr... - Pluang
ClearPoint Neuro stock slips as revenue misses estimates - ad-hoc-news.de
ClearPoint Neuro (CLPT) Stock Sees Fair Value Cut As Analysts Factor In Heavier Investment - Yahoo Finance
ClearPoint Neuro Company Profile & Introduction - Moomoo
How (CLPT) Movements Inform Risk Allocation Models - Stock Traders Daily
Lake Street Maintains ClearPoint Neuro(CLPT.US) With Buy Rating, Maintains Target Price $25 - Moomoo
ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024 - ACCESS Newswire
ClearPoint Neuro stock holds recent gains as earnings and analyst targets frame the next move - AD HOC NEWS
ClearPoint (CLPT) Quarter in Focus: The Bottom-Line Figure Trails Its Comparison at the Close; Price Reaction: Shares Finish 11.80% Up on the DaySubscription Growth Report - vinanet.vn
ClearPoint (CLPT) Results at a Glance: The Bottom-Line Figure Trails Its Comparison in the Current Update; Trading Response: Shares Fall 2.01% at the CloseBuyback Announcement Report - vinanet.vn
ClearPoint Neuro, Inc. (CLPT) Reports Q1 Loss, Lags Revenue Estimates - Eastern Progress
Conway Capital Management Inc. Makes New $1.66 Million Investment in ClearPoint Neuro, Inc. $CLPT - MarketBeat
ClearPoint Neuro (CLPT) Edges Lower as Shares Consolidate Between $14.57 Support and $16.11 ResistanceBullish Sentiment - vinanet.vn
ClearPoint Neuro (CLPT) Edges Lower as Shares Consolidate Between $14.57 Support and $16.11 ResistanceBullish Sentiment - vinanet.vn
(CLPT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
ClearPoint Neuro (CLPT): MAK Capital group discloses 7.8% ownership in 13G/A - Stock Titan
ClearPoint Neuro (CLPT) Q2 2026 Earnings Call Transcript - AOL.com
ClearPoint Neuro (CLPT) Q2 2026 Earnings Call Transcript - The Globe and Mail
ClearPoint Neuro (CLPT) Q2 2026 Earnings Call Transcript - The Globe and Mail
ClearPoint Neuro (CLPT) Jumps 6.12% to $14.21: Key Levels to WatchSell Signal Alerts - vinanet.vn
ClearPoint Neuro (NASDAQ:CLPT) Downgraded to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Clearpoint Neuro Inc (CLPT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Analysts Have Lowered Expectations For ClearPoint Neuro, Inc. (NASDAQ:CLPT) After Its Latest Results - 富途牛牛
Clearpoint Neuro Inc (CLPT) Stock News Today - TradingKey
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported And Analysts Have Been Cutting Their Estimates - simplywall.st
Analysts Have Lowered Expectations For ClearPoint Neuro, Inc. (NASDAQ:CLPT) After Its Latest Results - Moomoo
ClearPoint Neuro, Inc. (CLPT) Options Chain - Yahoo! Finance Canada
CLPT Looks 4.6% Overvalued on GF Value™ Ahead of Tuesday Market Drop - GuruFocus
ClearPoint Neuro: Regulatory Momentum Strengthens The Long-Term Investment Case (CLPT) - Seeking Alpha
ClearPoint Neuro Updates Q2 Results and 2026 Outlook - The Globe and Mail
ClearPoint Neuro (CLPT) investors disclose 7.45% beneficial ownership stake - Stock Titan
Lake Street Maintains ClearPoint Neuro(CLPT.US) With Buy Rating, Cuts Target Price to $25 - Moomoo
Stifel cuts Clearpoint Neuro stock price target on guidance cut - Investing.com
Stifel cuts Clearpoint Neuro stock price target on guidance cut By Investing.com - Investing.com South Africa
Stifel cuts Clearpoint Neuro stock price target on guidance cut By Investing.com - Investing.com Nigeria
Stifel cuts Clearpoint Neuro stock price target on guidance cut By Investing.com - Investing.com India
ClearPoint Neuro, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Powell Industries Posts Downbeat Q3 Results, Joins Clearpoint Neuro, Ichor Holdings And Other Big Stocks - Benzinga
CLPT Looks 4.7% Overvalued on GF Value™ - GuruFocus
CLPT Looks 4.7% Overvalued on GF Value™ - GuruFocus
How Does ClearPoint Neuro Inc (CLPT) Perform in Q2? EPS at -$0.3 - GuruFocus
Earnings call transcript: Clearpoint Neuro Q2 2026 misses estimates as shares fall - Investing.com Canada
ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Clearpoint Neuro Inc Stock (CLPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Clearpoint Neuro Inc Stock (CLPT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BURNETT JOSEPH | CEO and President |
Jun 29 '26 |
Sale |
19.38 |
20,000 |
387,600 |
116,842 |
| BURNETT JOSEPH | CEO and President |
Jun 29 '26 |
Option Exercise |
2.50 |
20,000 |
50,000 |
136,842 |
| JOSEPH BURNETT | Director |
Jun 29 '26 |
Proposed Sale |
18.48 |
20,000 |
369,600 |
0 |
| BURNETT JOSEPH | CEO and President |
Jun 17 '26 |
Option Exercise |
2.50 |
60,000 |
150,000 |
176,842 |
| BURNETT JOSEPH | CEO and President |
Jun 17 '26 |
Sale |
17.79 |
60,000 |
1,067,400 |
116,842 |
| BURNETT JOSEPH | CEO and President |
Jun 17 '26 |
Sale |
17.94 |
1,843 |
33,063 |
191,388 |
| JOSEPH M BURNETT TRUST | Affiliate of Director |
Jun 17 '26 |
Proposed Sale |
13.34 |
1,843 |
24,586 |
0 |
| JOSEPH BURNETT | Director |
Jun 17 '26 |
Proposed Sale |
13.34 |
60,000 |
800,400 |
0 |
| Richards Timothy T. | Director |
Jun 04 '26 |
Option Exercise |
10.00 |
500 |
5,000 |
87,698 |
| Richards Timothy T. | Director |
Jun 01 '26 |
Sale |
12.17 |
5,415 |
65,901 |
87,198 |
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):